Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
This was the stock's third consecutive day of losses.
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...
Regeneron announces FDA acceptance of BLA for linvoseltamab
Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors
This was the stock's second consecutive day of losses.